Telomerase In Cancer

26 March 1995

- According to a report from the American Association for Cancer Research, spontaneous tumor regression may be related to the absence of an enzyme known as telomerase. Jerry Shay, from the University of Texas in Dallas, said that it appears that cells are programmed to grow old if the chromosomes shorten beyond a critical length. However, telomerase attaches to the end of chromosomes in tumor cells and prevents this shortening, so effectively allowing the cell "immortality" seen in tumors. Dr Shay said that in a study of 100 neuroblastomas, telomerase was found in 94 out of 100 samples. Three of the samples which did not show telomerase activity were from a type of tumor found in children which often spontaneously regresses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight